RIGEL (RIGL) director Lapointe granted 5,750-share RSU-based stock award

Rhea-AI Filing Summary

LAPOINTE ANTHONY GREGG reported acquisition or exercise transactions in this Form 4 filing.

RIGEL PHARMACEUTICALS INC director Anthony Gregg Lapointe reported an equity compensation grant of 5,750 shares of Common Stock, recorded at a price of $0.00 per share. These shares are tied to a Restricted Stock Unit award that will fully vest on the date prior to the company’s next Annual Meeting, if he continues serving on the Board of Directors. Following this award, Lapointe’s reported direct holdings total 18,250 shares of Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LAPOINTE ANTHONY GREGG

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,750	$0.00	--

Holdings After Transaction: Common Stock — 18,250 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity award size: 5,750 shares Grant price per share: $0.00 per share Post-transaction holdings: 18,250 shares

3 metrics

Equity award size 5,750 shares Restricted Stock Unit-based Common Stock grant

Grant price per share $0.00 per share Reported transaction price for the RSU-related award

Post-transaction holdings 18,250 shares Common Stock directly held after the award

Key Terms

Restricted Stock Unit, Annual Meeting, Board of Directors, Common Stock

4 terms

Restricted Stock Unit financial

"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Annual Meeting financial

"The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

Board of Directors financial

"subject to the Reporting Person's continuous service on the Company's Board of Directors."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Common Stock financial

"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAPOINTE ANTHONY GREGG

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		A		5,750(1)	A	$0	18,250	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

	/s/ Raymond Furey (Attorney-in-Fact)	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did RIGL director Anthony Gregg Lapointe report on this Form 4?

Anthony Gregg Lapointe reported an acquisition of 5,750 shares of RIGEL PHARMACEUTICALS INC Common Stock through a grant. The award is structured as Restricted Stock Units that convert into shares upon vesting, rather than an open-market purchase for cash.

How many RIGL shares did Lapointe receive in this grant?

Lapointe received an award covering 5,750 shares of RIGEL PHARMACEUTICALS INC Common Stock. The grant is reported at a transaction price of $0.00 per share, reflecting that it is a compensation-related equity award rather than a market purchase transaction for cash consideration.

When will Anthony Gregg Lapointe’s RIGL Restricted Stock Units vest?

The Restricted Stock Units will fully vest on the date prior to RIGEL PHARMACEUTICALS INC’s next Annual Meeting. Vesting is contingent on Lapointe’s continuous service on the company’s Board of Directors through that date, aligning the grant with ongoing board service.

How many RIGL shares does Lapointe hold after this Form 4 transaction?

After this reported transaction, Anthony Gregg Lapointe holds 18,250 shares of RIGEL PHARMACEUTICALS INC Common Stock directly. This total reflects his position following the 5,750-share equity award described in the filing, as reported in the post-transaction ownership figure.

Was this RIGL Form 4 transaction an open-market buy or a compensation award?

This transaction was a compensation-related equity award, not an open-market purchase. The Form 4 classifies it as a grant or award acquisition of Common Stock via Restricted Stock Units, with a reported price of $0.00 per share, typical for non-cash director compensation.